BCL-2 and p53 expression in endometrial carcinoma

Erkanli S. , Eren F., Pekin S., Bagis T.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, cilt.23, sa.1, ss.97-103, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Konu: 1
  • Basım Tarihi: 2004
  • Sayfa Sayıları: ss.97-103


Our aim was to compare the results of bcl-2 expression in endometrial carcinoma with clinicopathological prognostic factors along with p53 accumulation. In addition, p53 expression was compared to different subtypes of endometrial carcinoma. Immunohistochemical staining was pet-formed on formalin-fixed, paraffin embedded tissue sections by using Bcl-2 Supersensitive Mouse Anti-Bcl-2 Oncoprotein (Biogenex AM287-5M) for bcl-2 immunostaining and Supersensitive Mouse Anti-p53 Suppressor Gene Product (1801) (Biogenex AM 240-5M) for p53 immunostaining. 9 out of 9 cases of proliferative endometrium, 515 cases of endometrial hyperplasia without atypia, 515 cases with atypia, and 21/35 cases of endometrial carcinoma showed bcl-2 protein expression. Bcl2 expression was not related to age, surgical stage, or histopathological features, nor was there an inverse correlation between bcl-2 and p53 expression in endometrial carcinoma. p53 expression was detected in 3/4 cases of serous papillary carcinoma, whereas only 5/31 cases of endometrioid carcinoma showed p53 expression.